Denali Therapeutics (DNLI) incurred a first-quarter 2024 loss of 68 cents per share, wider than the Zacks Consensus Estimate of a loss of 67 cents but narrower than the year-ago quarter’s loss of 80 cents.The year-over-year narrower loss was due to a decline in operating expenses.In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations in the top line. Denali did not generate any collaboration revenues in the reported quarter. The Zacks Consensus Estimate for re ...